Insiders who reported open-market trades in the last 12 months at the companies Garen G. Bohlin files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Scott Dreyer - $2.02M in COLL purchases and sales in the last 12 months
John A. Fallon - $1.65M in COLL purchases and sales in the last 12 months
Colleen Tupper - $1.22M in COLL purchases and sales in the last 12 months
David Dieter - $716K in COLL purchases and sales in the last 12 months
Nancy Lurker - $162K in COLL purchases and sales in the last 12 months
John Gordon Freund - $143K in COLL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Garen G. Bohlin is a corporate insider of Karyopharm Therapeutics Inc. (KPTI). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Garen G. Bohlin last file a Form 4?
The most recent primary Form 4 on record is dated 26 May 2026, one of 5 filings going back to 2025.
Has Garen G. Bohlin been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($323K) across all tracked filings.
Garen G. Bohlin files SEC Form 4 reports at Karyopharm Therapeutics Inc. (KPTI). 5 SEC Form 4 filings on record going back to 2025, most recently on 26 May 2026. Most recent open-market trade: sold $323K of COLL on 13 May 2026. Lifetime open-market sales: $323K.
Recent transactions
5
The latest 5 SEC Form 4 transactions reported by Garen G. Bohlin.
InsiderAlpha's records for Garen G. Bohlin go back to 2025: 5 primary Form 4 filings, an average of 2.5 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
